Dr. Ko was appointed to the science advisory board in 2018. He serves as the Director and Chief of Medical Dermatology for Stanford Health Care (SHC) while also spearheading the dermatology department's efforts around network development, digital health, quality/safety/performance improvement, and value-based care. He is active in a number of leadership roles within the organization including co-chairing the Clinic Advisory Council, a forum of medical and executive leaders of Stanford Health Care’s Ambulatory clinics, and as a Service Medical Director.
Dr. Ko has also been driven to find new treatments for alopecia areata, an immune-mediated condition that can progress to total hair loss through various clinical trials and translational research efforts. He sits on the clinical research advisory board of the National Alopecia Areata Foundation and is founder and co-director of the Skin Interventional and Innovation Research Group (SIIRG) which conducts clinical and translational research on skin disease.
He graduated magna cum laude from Harvard University and worked in investment banking; mergers and acquisitions at JP Morgan before going on to earn a combined medical and business degree at Tufts University. During medical school, he was a member of the Alpha Omega Alpha honor society. Dr. Ko then performed his residency at the Harvard Dermatology Residency Training Program where he served as chief resident.
Prof. Mitragotri is Hiller Professor of Bioengineering and Hansjorg Wyss Professor of Biologically Inspired Engineering at Harvard John A. Paulson School of Engineering and Applied Sciences. He has made groundbreaking contributions to the field of biological barriers and drug delivery. His research, which is focused on the fundamental understanding of biological barriers, has led to the development of new materials and technologies for diagnosis and treatment of various ailments including diabetes, cancer, cardiovascular diseases, skin conditions and infections. He is an elected member of the NAE and NAM, and an elected fellow of NAI, AAAS, CRS, BMES, AIMBE, and AAPS. Currently Prof. Mitragotri serves on a number of private company boards in addition to CAGE Bio and was appointed to his current position in 2018.
D r. Brett King is an Associate Professor of Dermatology, specializing in skin diseases recalcitrant to first-line therapies. He has pioneered the use of Janus kinase (JAK) inhibitors in cutaneous diseases, in particular for alopecia areata, vitiligo, and atopic dermatitis, in addition to other disorders. He sees patients at Yale Dermatology- Middlebury. He joined the CAGE Bio team in 2020.
He is experienced with the use of systemic medications including retinoids, methotrexate, cyclosporine, azathioprine (Imuran®), mycophenolate mofetil (Cellcept®), tofacitinib (Xeljanz®), ruxolitinib (Jakafi®), apremilast (Otezla®), and the ‘biologics’ (e.g. etanercept (Enbrel®), adalimumab (Humira®), infliximab (Remicade®), ustekinumab (Stelara®), sekucinumab (Cosentyx®), ixekizumab (Taltz®), IVIG, and rituximab (Rituxan®)), as well as phototherapy.
Dr. King received his B.A. at the University of California at Santa Cruz, his Ph.D. from Stanford University and his M.D. from Yale University School of Medicine. He completed medical internship at Massachusetts General Hospital and dermatology residency at Yale University School of Medicine.
Dr. Dhawan is a graduate of San Francisco State University and the University of Southern California School of Medicine. He completed an internship and residency in Internal Medicine at U.C.S.F followed by a residency in dermatology at Mount Sinai Hospital in Miami, where he was also Chief Resident. He is Board Certified in Internal Medicine and Dermatology. Dr. Dhawan is a Fellow of the American College of Physicians and the American Academy of Dermatology. He also is an Assistant Adjunct Professor at the Stanford University, Department of Dermatology, where he teaches dermatology residents and medical students. He joined CAGE Bio in 2018.
Dr. Sinclair was appointed to the science advisory board in 2019. He is a Professor of Dermatology at the University of Melbourne and Director of Epworth Dermatology. He is Past-President of the Australasian Society for Dermatology Research, the Australasian Hair and Wool Research Society and the Skin and Cancer Foundation of Victoria.
Prof Sinclair is the co-author of the section on Dermatology in the Oxford Textbook of Medicine, the hair Chapter in Rook and also Bologna and lead author of Therapeutic Guidelines- Dermatology. He has written 13 textbooks of dermatology and has over 400 research publications.
Prof Sinclair convened the World Congress of Cosmetic Dermatology in Melbourne in 2006 and the World Congress of Hair Research in Cairns in 2010. He also convened the Annual Scientific Meeting of the Australasian Society for Dermatology research each year from 1999-2012.
His main research interests are androgenetic alopecia, alopecia areata, skin cancer epidemiology, psoriasis, genetic diseases of the skin, autoimmune diseases of the skin, skin immunology and hair and skin stem cell biology.
Dr. Webster is an Ex-Clinical Professor of Dermatology at Thomas Jefferson University in Philadelphia, Pennsylvania. As an active member of the medical community, Dr. Webster belongs to numerous professional organizations. He is the founding president of the American Acne and Rosacea Society and a Fellow of the Pennsylvania Academy of Dermatology and of the American Academy of Dermatology.He is also a member of the Society for Investigative Dermatology. He was appointed to the advisory board in 2020.
Dr. Draelos joined the CAGE Bio team in 2020. She is a research and clinical board-certified dermatologist and a Fellow of the American Academy of Dermatology. She is in solo private practice in High Point, North Carolina, and a Consulting Professor of Dermatology at Duke University. In 1988, she founded Dermatology Consulting Services, PLLC, to initiate and perform research in aging skin, acne, rosacea, psoriasis, atopic dermatitis, actinic keratoses, eczema, and aesthetic procedures in the cosmetic, OTC drug, and pharmaceutical arenas. Prior to pursuing a medical career, Dr. Draelos completed an undergraduate degree in Mechanical Engineering and was elected a Rhodes Scholar. A member of Sigma Xi research honorary and Alpha Omega Alpha medical honorary, she is author of 14 books including Cosmetics in Dermatology and Hair Cosmetics and Cosmetic Dermatology: Products and Procedures, as well as the editor of Cosmeceuticals, now in its third edition and translated into 7 languages.
Dr. Phipps joined the board in 2018. He has 20+ years of experience in product development and has served as the Vice President of transdermal R&D at leading biotechs including Johnson & Johnson and Alza Corporation. He has also served as the Chief Scientific Officer (CSO) and VP of Scientific Affairs at Incline Therapeutics, a subsidiary of The Medicines Company.
CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic Liquid formulation of 1% Tofacitinib In Patients with Atopic Dermatitis